{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024430","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.795041+00:00","generated_at":"2026-06-21T23:58:02.891186+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rani Therapeutics Q3 2022 net loss $16.2M; cash $98.7M; pipeline progress highlighted","bullets":["Cash, cash equivalents, restricted cash equivalents and marketable securities totaled $98.7M at Sept 30, 2022, down from $117.5M at Dec 31, 2021.","Net loss of $16.2M compared to $28.7M in Q3 2021; R&D expenses $9.1M, G&A expenses $7.2M.","RT-102 Phase 1 Part 2 repeat-dose data expected in Q4 2022; positive Part 1 showed 300-400% greater bioavailability vs subcutaneous Forteo.","RT-111 (ustekinumab biosimilar) preclinical development announced; Phase 1 planned in 2023.","$30M committed loan from Avenue Venture Opportunities; up to $150M at-the-market equity offering program."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024430","json":"https://secwatch.observer/filing/0000950170-22-024430.json","markdown":"https://secwatch.observer/filing/0000950170-22-024430.md","text":"https://secwatch.observer/filing/0000950170-22-024430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017022024430/0000950170-22-024430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017022024430/rani-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:58:02.891186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}